Argen X SE ADR Dossier - Source-backed chat

Argen X SE ADR

ARGXEuronext Brussels

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.32

Intrinsic Value $1,124.03median of 5 methods · middle span $936-$5,361based on filings through 31 Dec 2025

Market Price $958.91Price as of 30 Sep 2026

UndervaluedIntrinsic value is 17% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $59.6B

Enterprise Value $56.2B

Shares Outstanding 61.3M diluted

Moat Rating Wide

Next Earnings Date22 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

argenx has strong operating momentum from broader VYVGART adoption, an expanded U.S. label covering all adult generalized-myasthenia-gravis serotypes, and positive Phase 3 autoimmune-myositis data that could extend the FcRn franchise into rheumatology. The medium-term opportunity also includes empasiprubart and a widening clinical pipeline.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets22 analysts · as of 18 Aug 2026

Low · most bearish analyst$770.00

Mean target$1,098.32

High · most bullish analyst$1,350.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$770.0017%

Regulatory conversion of ALKIVIA is slower than expected, EMPASSION fails to establish empasiprubart as a second franchise, or additional development timelines slip. Those outcomes would increase dependence on existing VYVGART indications and reduce confidence in achieving the company's 2030 patient, indication and pipeline objectives.

Base CaseCentral scenario

$1,098.3258%

Matches the consensus mean

VYVGART remains the principal growth engine, the all-serotype generalized-myasthenia-gravis label and positive myositis data support continued franchise expansion, and pipeline programs advance with normal clinical and regulatory delays.

Bull CaseUpside scenario

$1,350.0025%

VYVGART adoption continues to broaden across generalized myasthenia gravis and CIDP, the positive ALKIVIA result converts into an additional approved indication, and EMPASSION validates empasiprubart as a second meaningful franchise. This would place the company ahead of its path toward 50,000 treated patients, 10 labeled indications and five pipeline candidates in registrational development by 2030.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

The last officially disclosed patient count was approximately 19,000, and the subsequently expanded U.S. label made VYVGART and VYVGART Hytrulo available across all adult generalized-myasthenia-gravis serotypes.
ALKIVIA met its Phase 3 primary endpoint in the combined IMNM and dermatomyositis population, with an early and sustained treatment benefit and no new safety signal reported.
Management expects ten molecules in clinical development by the end of 2026, while empasiprubart has registrational programs in MMN and CIDP.

Key Investment Risks

Current approved indications remain centered on the efgartigimod/VYVGART franchise, making successful execution of label expansion and pipeline diversification important.
Clinical results may not translate into regulatory approval, reimbursement, market acceptance or commercially meaningful adoption.
Development schedules can move: the expected ADVANCE-NEXT primary-ITP readout shifted from the fourth quarter of 2026 to the first half of 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.